Omer Onder

Omer Onder

Auto-generated profile, based on publicly available information

Omer Onder

Department of Radiology, Division of Cardiothoracic Imaging, University of Pittsburgh Medical Center, 203 Lothrop St, EEI Ste 700, Pittsburgh, PA 15213

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2019 in European Journal of Breast Health
Verified
Journal Article
Closed access
GDGamze Durhan
Gamze Durhan
AAAynur Azizova
Aynur Azizova
OOOmer Onder
Omer Onder
KKKemal Kosemehmetoglu
Kemal Kosemehmetoglu
JKJale Karakaya
Jale Karakaya
AUAysegul Uner
Aysegul Uner
Eur J Breast Health AVES | Copyright © 2017 Türkiye Meme Hastalıkları Dernekleri Federasyonu |

1 May 2024 in Diagnostic and Interventional Radiology
Verified
Journal Article
Open access
ÖÖÖmer Önder
Ömer Önder
MAMüjdat Ayva
Müjdat Ayva
YYYasin Yaraşır
Yasin Yaraşır
VGVolkan Gürler
Volkan Gürler
SYSertac Yazici
Sertac Yazici
DADeniz Akata
Deniz Akata
We aim to examine the long-term outcomes of patients who underwent multiparametric prostate magnetic resonance imaging (mp-MRI) for suspected prostate cancer (PCa), specifically based on their initial Prostate Imaging Reporting and Data System (PI-RADS) categories and various clinical factors. Our secondary aim is to evaluate the prognostic value of the PI-RADS through the National Comprehensive Cancer Network (NCCN) risk group distribution. This research was conducted as a single-center retrospective cohort study in a tertiary care hospital. A total of 1,359 cases having at least one histopathological examination after the initial mp-MRI and/or adequate clinical/radiological follow-up data were included in the clinically significant PCa (cs-PCa) diagnosis-free survival analysis. Initial mp-MRI dates were accepted as the start of follow-up for the time-to-event analysis. The event was defined as cs-PCa diagnosis (International Society of Urological Pathology ≥2). Patients who were not diagnosed with cs-PCa during follow-up were censored according to predefined literature-based criteria at the end of the maximum follow-up duration with no reasonable suspicion of PCa and no biopsy indication. The impact of various factors on survival was assessed using a log-rank test and multivariable Cox regression. Subsequently, 394 cases diagnosed with PCa during follow-up were evaluated, based on initial PI-RADS categories and NCCN risk groups. Three main risk factors for cs-PCa diagnosis during follow-up were an initial PI-RADS 5 category, initial PI-RADS 4 category, and high MRI-defined PSA density (mPSAD), with average hazard ratios of 29.52, 14.46, and 3.12, respectively. The PI-RADS 3 category, advanced age group, and biopsy-naïve status were identified as additional risk factors (hazard ratios: 2.03, 1.54-1.98, and 1.79, respectively). In the PI-RADS 1-2 cohort, 1, 3, and 5-year cs-PCa diagnosis-free survival rates were 99.1%, 96.5%, and 93.8%, respectively. For the PI-RADS 3 cohort, 1, 3, and 5-year cs-PCa diagnosis-free survival rates were 94.9%, 90.9%, and 89.1%, respectively. For the PI-RADS 4 cohort, 1, 3, and 5-year cs-PCa diagnosis-free survival rates were 56.6%, 55.1%, and 55.1%, respectively. These rates were found to all be 24.2% in the PI-RADS 5 cohort. Considering the 394 cases diagnosed with PCa during follow-up, PI-RADS ≥4 cases were more likely to harbor unfavorable PCa compared to PI-RADS ≤3 cases (p < 0.001). In the PI-RADS 3 subgroup analysis, a low mPSAD (<0.15 ng/mL2) was found to be a protective prognostic factor against unfavorable PCa (P = 0.005). The PI-RADS category has a significant impact on patient management and provides important diagnostic and prognostic information. Higher initial PI-RADS categories are associated with decreased follow-up losses, a shorter time to PCa diagnosis, increased biopsy rates, a higher likelihood of developing cs-PCa during follow-up, and a worse PCa prognosis. Combining mPSAD with PI-RADS categories could enhance diagnostic stratification in the identification of cs-PCa.

2 July 2019 in European Journal of Breast Health
Verified
Journal Article
Closed access
GDGamze Durhan
Gamze Durhan
OOOmer Onder
Omer Onder
AAAynur Azizova
Aynur Azizova
JKJale Karakaya
Jale Karakaya
KKKemal Kosemehmetoglu
Kemal Kosemehmetoglu
FDFigen Başaran Demirkazïk
Figen Başaran Demirkazïk
Eur J Breast Health AVES | Copyright © 2017 Türkiye Meme Hastalıkları Dernekleri Federasyonu |

1 May 2026 in RadioGraphics
Verified
Journal Article
Closed access
OOOmer Onder
Omer Onder
EDEMRAH DUMAN
EMRAH DUMAN
BCBrittany Cody
Brittany Cody
ZKZehavit E. Kirshenboim
Zehavit E. Kirshenboim
IOIclal Ocak
Iclal Ocak
Subsolid nodules and atypical pulmonary cysts can pose diagnostic challenges due to their slow growth and atypical imaging features, and improved understanding of their imaging hallmarks, pathologic correlations, guideline-based recommendations, and risk assessment strategies is essential for accurately identifying pulmonary adenocarcinomas that may arise from these potentially malignant lesions.

7 July 2021 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
OOOmer Onder
Omer Onder
AKAli Devrim Karaosmanoglu
Ali Devrim Karaosmanoglu
JKJessica Kraeft
Jessica Kraeft
AUAycan Uysal
Aycan Uysal
MKMusturay Karcaaltincaba
Musturay Karcaaltincaba
PHPeter F. Hahn
Peter F. Hahn
Tumors of the genital system are common and imaging is of crucial importance for their detection and diagnosis. Several non-neoplastic diseases may mimic these tumors and differential diagnosis may be difficult in certain cases. Misdiagnosing non-neoplastic diseases as tumor may prompt unnecessary medical treatment or surgical interventions. In this article, we aimed to present the imaging characteristics of non-neoplastic diseases of the male and female genital systems that may mimic neoplastic processes. Increasing awareness of the imaging specialists to these entities may have a severe positive impact on the management of these patients.